Velaglucerase alfa

Velaglucerase alfa
Names
Trade namesVpriv
Clinical data
Main usesGaucher disease type 1[1]
Side effectsAbdominal pain, headache, dizziness, bone pain, infusion-related reactions, tiredness, fever[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		Intravenous
Typical dose15–60 units/kg[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetics
BioavailabilityN/A
Elimination half-lifePlasma: 5–12 minutes (absorbed by macrophages)
Chemical and physical data
FormulaC2532H3850N672O711S16
Molar mass55593.61 g·mol−1

Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for Gaucher disease type 1.[1] It is given by gradual injection into a vein every two weeks.[1] Effectiveness is similar to imiglucerase.[2]

Common side effects include abdominal pain, headache, dizziness, bone pain, infusion-related reactions, tiredness, and fever.[2] Antibodies against the medication may form.[3] It works by replacing the missing enzyme glucocerebrosidase and thus facilitating the breakdown of glucocerebroside.[2]

Velaglucerase alfa was approved for medical use in Europe and the United States in 2010.[2][3] In the United Kingdom 400 units costs the NHS about £1,400 as of 2021.[1] This amount in the United States costs about 1,500 USD.[4] In Canada for a typical 70 kg individual the medication costs about 150,000 to 560,000 CAD a year as of 2017.[5] It is made by recombinant DNA techniques.[1]

Medical uses

Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.[2][6]

Dosage

It is given at a dose of 15–60 units/kg every two weeks.[1]

Competitive products

Imiglucerase is Genzyme's version of recombinant glucocerebrosidase.

In addition, Protalix and Pfizer have received approval for marketing taliglucerase alpha in Israel, Brazil, Canada and the U.S. The companies are expected also to file for marketing authorization in Europe and elsewhere around the world.

References

  1. 1 2 3 4 5 6 7 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1125. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  2. 1 2 3 4 5 6 "Vpriv EPAR". European Medicines Agency (EMA). Archived from the original on 29 October 2020. Retrieved 13 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. 1 2 "Velaglucerase Alfa Monograph for Professionals". Drugs.com. Retrieved 13 September 2021.
  4. ↑ "VPRIV Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 18 April 2021. Retrieved 13 September 2021.
  5. ↑ "Table 12, CDR Cost Comparison Table for Drug Therapies for GD1". www.ncbi.nlm.nih.gov. CADTH. August 2017. Archived from the original on 22 September 2021. Retrieved 13 September 2021.
  6. ↑ "Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution". DailyMed. 18 June 2020. Archived from the original on 24 March 2021. Retrieved 13 August 2020.
Identifiers:
  • "Velaglucerase alfa". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2021-08-27. Retrieved 2021-01-23.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.